Part IV. Human infections and antibiotic resistance

South African Medical Journal

Volumn 101, Issue 8, 2011, Pages 567-568

  Crowther Gibson, P ^a   Govender, N ^a   Lewis, D A ^a   Bamford, C ^a   Brink, A ^a   von Gottberg, A ^a   Klugman, K ^a   du Plessis, M ^a   Fali, A ^a   Harris, B ^a   Keddy, K H ^a   Botha, M ^a  

^a NONE

Author keywords

Acute respiratory infection; Antibiotic (antimicrobial) resistance; Antibiotics; Enteric infections; Hospital acquired infections; Pneumonia; Sexually transmitted infections

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; COTRIMOXAZOLE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; CAUSE OF DEATH; CHILDHOOD MORTALITY; CHOLERA; DEVELOPING COUNTRY; DIARRHEA; DRUG TREATMENT FAILURE; FLUID THERAPY; GASTROENTERITIS; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; MENINGOCOCCEMIA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PNEUMOCOCCAL MENINGITIS; PUBLIC HEALTH PROBLEM; RESPIRATORY TRACT INFECTION; SALMONELLOSIS; SEXUALLY TRANSMITTED DISEASE; SHIGELLOSIS; SOUTH AFRICA; STREPTOCOCCUS PNEUMONIA; TUBERCULOSIS; TYPHOID FEVER; VIBRIOSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HEALTH PROMOTION; HUMANS; NATIONAL HEALTH PROGRAMS; PRESCRIPTION DRUGS; PRIMARY HEALTH CARE; SOUTH AFRICA;

EID: 79961006831     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (136)

1. Norman R, Bradshaw D, Schneider M, Pieterse D, Groenewald P. Revised Burden of Disease Estimates for the Comparative Risk Factor Assessment, South Africa 2000. Methodological Note. Cape Town: South African Medical Research Council, Unit BoDR, 2006: 22.
2. Day C, Gray A. Chapter 21: Health and Related Indicators, p 283. In: Fonn A, Padarath A, eds. South African Health Review. Durban: Health Systems Trust, 2010.
3. BMI. South Africa Pharmaceuticals and Healthcare Report. London: 2010.
4. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992;14(4):801-807.
5. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. Wkly Epidemiol Rec 2007 Mar 23;82(12):93-104.
6. World Health Organization. Management of the young child with an acute respiratory infection. Program for control of acute respiratory infections. Geneva: WHO, 1990.
7. Du Plessis M, Smith AM, Klugman K P. Rapid detection of penicillin-resistant Streptococcus pneumoniae in cerebrospinal fuid by a seminested-PCR strategy. J Clin Microbiol 1998;36(2):453-457.
8. Hansman D, Bullen M. A resistant pneumococcus. Lancet 1967;2:264-265.
9. Appelbaum PC, Bhamjee A, Scragg JN, Hallett A F, Bowen AJ, Cooper RC. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977;2:995-997.
10. Jacobs MR, Koornhof HJ. Multiple-antibiotic resistance - now the pneumococcus. J Antimicrob Chemother 1978;4(6):481-483.
11. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978;299(14):735-740.
12. Allen KD. Penicillin-resistant pneumococci. J Hosp Infect 1991;17(1):3-13.
13. Friedland IR, Klugman K P. Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 1992;339:405-408.
14. Klugman K P, Walsh AL, Phiri A, Molyneux EM. Mortality in penicillin-resistant pneumococcal meningitis. Pediatr Infect Dis J 2008;27(7):671-672.
15. Dagan R, Leibovitz E, Leiberman A, Yagupsky P. Clinical signifcance of antibiotic resistance in acute otitis media and implication of antibiotic treatment on carriage and spread of resistant organisms. Pediatr Infect Dis J 2000;19(5 Suppl):S57-65.
16. Catalan MJ, Fernandez JM, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quiros JC. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis 1994;18(5):766-769.
17. Klugman K P. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl 2002;36:3s-8s.
18. Weinstein M P, Klugman K P, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009;48(11):1596-1600.
19. McGee L, McDougal L, Zhou J, et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defned by the pneumococcal molecular epidemiology network. J Clin Microbiol 2001;39(7):2565-2571.
20. Benbachir M, Benredjeb S, Boye CS, et al. Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities. Antimicrob Agents Chemother 2001;45(2):627-629.
21. Ramdani-Bouguessa N, Rahal K. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolated in Algiers, Algeria. Antimicrob Agents Chemother 2003;47(2):824-826.
22. Wasfy MO, Pimentel G, Abdel-Maksoud M, et al. Antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Egypt, 1998-2003. J Antimicrob Chemother 2005;55(6):958-964.
23. Ohene A. Bacterial pathogens and their antimicrobial susceptibility in Kumasi, Ghana. East Afr Med J 1997;74(7):450-455.
24. Adegbola RA, Hill PC, Secka O, et al. Serotype and antimicrobial susceptibility patterns of isolates of Streptococcus pneumoniae causing invasive disease in Te Gambia 1996-2003. Trop Med Int Health 2006;11(7):1128-1135.
25. Erqou S, Kebede Y, Mulu A. Increased resistance of Streptococcus pneumoniae isolates to antimicrobial drugs, at a referral hospital in north-west Ethiopia. Trop Doct 2008;38(2):110-112.
26. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000;45(2):191-203.
27. Muhe L, Klugman K P. Pneumococcal and Haemophilus infuenzae meningitis in a children's hospital in Ethiopia: serotypes and susceptibility patterns. Trop Med Int Health 1999;4(6):421-427.
28. Feikin DR, Davis M, Nwanyanwu OC, et al. Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatr Infect Dis J 2003;22(6):564-567.
29. Woolfson A, Huebner R, Wasas A, Chola S, Godfrey-Faussett P, Klugman K. Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. Bull World Health Organ 1997;75(5):453-462.
30. Valles X, Flannery B, Roca A, et al. Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae among children in rural Mozambique. Trop Med Int Health 2006;11(3):358-366.
31. Felmingham D, Feldman C, Hryniewicz W, et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. Clin Microbiol Infect 2002;8 Suppl 2:12-42.
32. Klugman K P, Koornhof HJ. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fuid or blood, 1979-1986. J Infect Dis 1988;158(5):956-964.
33. Koornhof HJ, Wasas A, Klugman K. Antimicrobial resistance in Streptococcus pneumoniae: a South African perspective. Clin Infect Dis 1992;15(1):84-94.
34. Huebner RE, Wasas AD, Klugman K P. Trends in antimicrobial resistance and serotype distribution of blood and cerebrospinal fuid isolates of Streptococcus pneumoniae in South Africa, 1991-1998. Int J Infect Dis 2000;4(4):214-218.
35. Huebner RE, Wasas AD, Klugman K P. Prevalence of nasopharyngeal antibiotic-resistant pneumococcal carriage in children attending private paediatric practices in Johannesburg. S Afr Med J 2000;90(11):1116-1121.
36. Liebowitz LD, Slabbert M, Huisamen A. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifoxacin compared with eight other antimicrobial agents. J Clin Pathol 2003;56(5):344-347.
37. Buie KA, Klugman K P, von Gottberg A, et al. Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia. J Infect Dis 2004;189(11):1996-2000.
38. Pemba L, Charalambous S, von Gottberg A, et al. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. J Infect 2008;56(3):171-178.
39. Feldman C, Brink AJ, von Gottberg A, et al. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fuoroquinolone pharmacodynamics. Int J Antimicrob Agents 2010;36(1):95-97.
40. Campbell GD, Jr., Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998;26(5):1188-1195.
41. Doern G V, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg Infect Dis 1999;5(6):757-765.
42. Fenoll A, Gimenez MJ, Robledo O, et al. Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2008;27(1):75-80.
43. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343(26):1917-1924.
44. Wolter N, von Gottberg A, du Plessis M, de Gouveia L, Klugman K P. Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005. Int J Antimicrob Agents 2008;32(1):62-67.
45. Klugman K P, Koornhof HJ, Kuhnle V. Clinical and nasopharyngeal isolates of unusual multiply resistant pneumococci. Am J Dis Child 1986;140(11):1186-1190.
46. Klugman K P, Koornhof HJ, Wasas A, Storey K, Gilbertson I. Carriage of penicillin resistant pneumococci. Arch Dis Child 1986;61(4):377-381.
47. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fuoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341(4):233-239.
48. Von Gottberg A, Klugman K P, Cohen C, et al. Emergence of levofoxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008;371(9618):1108-1113.
49. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004;50 Suppl 1:3-10.
50. Siira L, Rantala M, Jalava J, et al. Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006. Antimicrob Agents Chemother 2009;53(5):2066-2073.
51. Syrogiannopoulos GA, Grivea IN, Davies TA, Katopodis GD, Appelbaum PC, Beratis NG. Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the frst 2 years of life. Clin Infect Dis 2000;31(4):887-893.
52. Okeke IN, Laxminarayan R, Bhutta ZA, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 2005;5(8):481-493.
53. Zerouali K, Elmdaghri N, Boudouma M, Benbachir M. Serogroups, serotypes, serosubtypes and antimicrobial susceptibility of Neisseria meningitidis isolates in Casablanca, Morocco. Eur J Clin Microbiol Infect Dis 2002;21(6):483-485.
54. Aff S, Wasfy MO, Azab MA, et al. Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004). Eur J Clin Microbiol Infect Dis 2007;26(5):331-340.
55. Gagneux S, Hodgson A, Ehrhard I, et al. Microheterogeneity of serogroup A (subgroup III) Neisseria meningitidis during an outbreak in northern Ghana. Trop Med Int Health 2000 Apr;5(4):280-287.
56. Norheim G, Rosenqvist E, Asefa A, et al. Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. J Clin Microbiol 2006;44(3):861-871.
57. Emele FE. Etiologic spectrum and pattern of antimicrobial drug susceptibility in bacterial meningitis in Sokoto, Nigeria. Acta Paediatr 2000;89(8):942-946.
58. Botha P. Penicillin-resistant Neisseria meningitidis in southern Africa. Lancet 1988;1:54.
59. Du Plessis M, von Gottberg A, Cohen C, de Gouveia L, Klugman K P. Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005. J Clin Microbiol 2008;46(10):3208-3214.
60. Du Plessis M, de Gouveia L, Skosana H, et al. Invasive Neisseria meningitidis with decreased susceptibility to fuoroquinolones in South Africa, 2009. J Antimicrob Chemother 2010;65(10):2258-2260.
61. Cardines R, Giufre M, Mastrantonio P, Ciofdegli Atti ML, Cerquetti M. Nontypeable Haemophilus infuenzae meningitis in children: phenotypic and genotypic characterization of isolates. Pediatr Infect Dis J 2007;26(7):577-582.
62. World Health Organization. Haemophilus infuenzae Type B (HiB): WHO Fact Sheet. Geneva: World Health Organization, 2005.
63. Peltola H. Worldwide Haemophilus influenza type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13(2):302-317.
64. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenza type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-1197.
65. Mwangi I, Berkley J, Lowe B, Peshu N, Marsh K, Newton CR. Acute bacterial meningitis in children admitted to a rural Kenyan hospital: increasing antibiotic resistance and outcome. Pediatr Infect Dis J 2002;21(11):1042-1048.
66. Tomeh MO, Starr SE, McGowan JE, Jr., Terry PM, Nahmias AJ. Ampicillin-resistant Haemophilus infuenzae type B infection. JAMA 1974;229(3):295-297.
67. Cerquetti M, Cardines R, Giufre M, Mastrantonio P. Antimicrobial susceptibility of Haemophilus infuenzae strains isolated from invasive disease in Italy. J Antimicrob Chemother 2004;54(6):1139-1143.
68. Tamargo I, Fuentes K, Llop A, Oteo J, Campos J. High levels of multiple antibiotic resistance among 938 Haemophilus infuenzae type b meningitis isolates from Cuba (1990-2002). J Antimicrob Chemother 2003;52(4):695-698.
69. Roca A, Quinto L, Abacassamo F, et al. Invasive Haemophilus infuenzae disease in children less than 5 years of age in Manhica, a rural area of southern Mozambique. Trop Med Int Health 2008;13(6):818-826.
70. Scott JA, Mwarumba S, Ngetsa C, et al. Progressive increase in antimicrobial resistance among invasive isolates of Haemophilus influenza obtained from children admitted to a hospital in Kilif, Kenya, from 1994 to 2002. Antimicrob Agents Chemother 2005;49(7):3021-3024.
71. Brink AJ, Cotton MF, Feldman C, et al. Guideline for the management of upper respiratory tract infections. S Afr Med J 2004;94(6 Pt 2):475-483.
72. Feldman C, Brink AJ, Richards GA, Maartens G, Bateman ED. Working Group of the South African Toracic Society. Management of community-acquired pneumonia in adults. S Afr Med J 2007;97(12):1296-1304
73. Daza P, Banda R, Misoya K, et al. The impact of routine infant immunization with Haemophilus infuenzae type b conjugate vaccine in Malawi, a country with high human immunodefciency virus prevalence. Vaccine 2006;24(37-39):6232-6239.
74. Ndiaye G, Edwige H, Guèye FB, Boye CSB. Trend in antibiotic resistance of Streptococcus pneumoniae and Haemophilus infuenzae strains isolated from community acquired respiratory tract infections in Dakar, Senegal between 2005 and 2008. Microbiology Insights 2010;3:45-52.
75. Fali A, du Plessis M, Wolter N, Klugman K P, von Gottberg A. Single report of beta-lactam resistance in an invasive Haemophilus infuenzae isolate from South Africa mediated by mutations in penicillin-binding protein 3, 2003-2008. Int J Antimicrob Agents 2010;36(5):480-482.
76. Garcia-Cobos S, Campos J, Lazaro E, et al. Ampicillin-resistant non-beta-lactamase-producing Haemophilus infuenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefxime. Antimicrob Agents Chemother 2007;51(7):2564-25673.
77. Matic V, Bozdogan B, Jacobs MR, Ubukata K, Appelbaum PC. Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in beta-lactamase-positive, amoxicillin/ clavulanate-resistant Haemophilu s infuenzae. J Antimicrob Chemother 2003;52(6):1018-1021.
78. Osaki Y, Sanbongi Y, Ishikawa M, et al. Genetic approach to study the relationship between penicillin-binding protein 3 mutations and Haemophilus infuenzae beta-lactam resistance by using site-directed mutagenesis and gene recombinants. Antimicrob Agents Chemother 2005;49(7):2834-2839.
79. Jansen W T, Verel A, Beitsma M, Verhoef J, Milatovic D. Longitudinal European surveillance study of antibiotic resistance of Haemophilus infuenzae. J Antimicrob Chemother 2006;58(4):873-877.
80. Kaczmarek FS, Gootz TD, Dib-Hajj F, Shang W, Hallowell S, Cronan M. Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus infuenzae with unusually high resistance to ampicillin. Antimicrob Agents Chemother 2004;48(5):1630-1639.
81. Kim IS, Ki CS, Kim S, et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus infuenzae strains isolated in Korea. Antimicrob Agents Chemother 2007;51(2):453-460.
82. Mandomando I, Sigauque B, Morais L, et al. Antimicrobial drug resistance trends of bacteremia isolates in a rural hospital in southern Mozambique. Am J Trop Med Hyg 2010;83(1):152-157.
83. Molyneux E, Walsh A, Phiri A, Molyneux M. Acute bacterial meningitis in children admitted to the Queen Elizabeth Central Hospital, Blantyre, Malawi in 1996-97. Trop Med Int Health 1998;3(8):610-618.
84. Ndip RN, Ntiege EA, Ndip LM, Nkwelang G, Akoachere JF, Akenji TN. Antimicrobial resistance of bacterial agents of the upper respiratory tract of school children in Buea, Cameroon. J Health Popul Nutr 2008;26(4):397-404.
85. Turnidge J, Bell J. Emerging beta-lactamase-negative ampicillin resistant Haemophilus infuenzae in Japan and South Africa (Abstract). Chicago: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 14-17 September 2003:C2-1268.
86. Parry CM, Trelfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis [Review] 2008;21(5):531-538.
87. Smith AM, Govender N, Keddy KH. Quinolone-resistant Salmonella typhi in South Africa, 2003-2007. Epidemiol Infect 2010;138(1):86-90.
88. Govender N, Smith AM, Karstaedt AS, Keddy KH. Plasmid-mediated quinolone resistance in Salmonella from South Africa. J Med Microbiol 2009;58(Pt 10):1393-1394.
89. Kruger T, Szabo D, Keddy KH, et al. Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother 2004;48(11):4263-4270.
90. Govinden U, Mocktar C, Moodley P, Sturm AW, Essack SY. CTX-M-37 in Salmonella enterica serotype Isangi from Durban, South Africa. Int J Antimicrob Agents 2006;28(4):288-291.
91. Govinden U, Mocktar C, Moodley P, Sturm A, Essack S. Detection of mutations in the gyrA of clinical Salmonella spp. African Journal of Biotechnology 2009;8(16):3911-3914.
92. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82(5):346-353.
93. Aarestrup FM, Wiuf C, Molbak K, Trelfall EJ. Is it time to change fuoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003;47(2):827-829.
94. Keddy KH, Smith AM, Sooka A, Ismail H, Oliver S. Fluoroquinolone-resistant typhoid, South Africa. Emerg Infect Dis 2010;16(5):879-880.
95. Pfeifer Y, Matten J, Rabsch W. Salmonella enterica serovar Typhi with CTX-M beta-lactamase, Germany. Emerg Infect Dis 2009;15(9):1533-1535.
96. Mahon C, Lehman D, Manuselis G. Enterobacteriaceae, Shigella. Diagnostic Microbiology, 3rd ed. St. Louis: Saunders Elsevier; 2007:521-523.
97. Smith AM, Keddy KH, Sooka A, Ismail H, Dejong GM. Analysis of a temporal cluster of Shigella boydii isolates in Mpumalanga, South Africa, November to December 2007. J Infect Dev Ctries 2009;3(1):65-70.
98. Mahon C, Lehman D, Manuselis G. Vibr io, Aeromonas and Campylobacter species. In: Diagnostic Microbiology. 3rd ed. St Louis: Saunders Elseiver; 2007:521-523.
99. Heymann D. Vibrio cholerae serogroups 01 and 0139. In: Control of Communicable Diseases Manual. 19th ed. Washington, DC: American Public Health Association, 2008:120-128.
100. Keddy K. Cholera outbreak in South Africa: extended laboratory characterisation of isolates. In: National Health Laboratory Service - Annual report 2009/2010. Sandringham, GA: National Health Laboratory Service, 2010:112.
101. Keddy K. Molecular characterisation of multidrug resistant cholera outbreak isolates. In: National Health Laboratory Service - Annual report 2009/2010. Sandringham, GA: National Health Laboratory Service, 2010:112.
102. Mahon C, Lehman D, Manuselis G. Enterobacteriaceae, Escherichia coli. Diagnostic Microbiology. 3rd ed. St. Louis: Saunders Elseiver, 2007:505-512.
103. Heymann D. Diarrhea, acute - diarrhea caused by Escherichia coli. In: Control of Communicable Diseases Manual. 19th ed. Washington, DC: American Public Health Association, 2008:181-195.
104. Peirano G, van Greune CH, Pitout JD. Characteristics of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli from community hospitals in South Africa. Diagn Microbiol Infect Dis 2011;69(4):449-453.
105. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999;75(1):3-17.
106. Telzak EE, Spitalny KC, Faur YC, et al. Risk factors for infection with plasmid-mediated high-level tetracycline resistant Neisseria gonorrhoeae. Sex Transm Dis 1989;16(3):132-136.
107. Pettifor A, Walsh J, Wilkins V, Raghunathan P. How effective is syndromic management of STDs? A review of current studies. Sex Transm Dis 2000;27(7):371-385.
108. Sahin-Hodoglugil NN, Woods R, Pettifor A, Walsh J. A comparison of cost-efectiveness of three protocols for diagnosis and treatment of gonococcal and chlamydial infections in women in Africa. Sex Transm Dis 2003;30(5):455-469.
109. Schneider H, Blaauw D, Dartnall E, Coetzee DJ, Ballard RC. STD care in the South African private health sector. S Afr Med J 2001;91(2):151-156.
110. Chabikuli N, Schneider H, Blaauw D, Zwi AB, Brugha R. Quality and equity of private sector care for sexually transmitted diseases in South Africa. Health Policy Plan 2002;17 Suppl:40-46.
111. Schneider H, Chabikuli N, Blaauw D, Funani I, Brugha R. Sexually transmitted infections - factors associated with quality of care among private general practitioners. S Afr Med J 2005;95(10):782-785.
112. Suchland RJ, Sandoz KM, Jefrey BM, Stamm WE, Rockey DD. Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. Antimicrob Agents Chemother 2009;53(11):4604-4611.
113. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000;181(4):1421-1427.
114. Bjornelius E, Anagrius C, Bojs G, et al. Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial. Sex Transm Infect 2008;84(1):72-76.
115. Hamasuna R, Osada Y, Jensen JS. Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR. Antimicrob Agents Chemother 2005;49(12):4993-4998.
116. Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004;351(2):154-158.
117. Dangor Y, Miller SD, Exposto Fda L, Koornhof HJ. Antimicrobial susceptibilities of southern African isolates of Haemophilus ducreyi. Antimicrob Agents Chemother 1988;32(9):1458-1460.
118. Moodley P, Sturm AW. Ciprofoxacin-resistant gonorrhoea in South Africa. Lancet 2005;366(9492):1159.
119. Lewis D. Antibiotic resistant gonococci - past, present and future. S Afr Med J 2007;97:1146-1150.
120. National Department of Health. First Line Comprehensive Management and Control of Sexually Transmitted Infections (STIs): Protocol for the Management of a Person with a Sexually Transmitted Infection according to the Essential Drugs List. Pretoria: National Department of Health, 2008.
121. De Jongh M, Dangor Y, Adam A, Hoosen AA. Gonococcal resistance: evolving from penicillin, tetracycline to the quinolones in South Africa - implications for treatment guidelines. Int J STD AIDS 2007;18(10):697-699.
122. Lewis DA, Scott L, Slabbert M, et al. Escalation in the relative prevalence of ciprofoxacin-resistant gonorrhoea among men with urethral discharge in two South African cities: association with HIV seropositivity. Sex Transm Infect 2008;84(5):352-355.
123. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefxime at a 6-h interval. J Infect Chemother 2003;9(1):35-39.
124. Lewis DA. Te gonococcus fights back: is this time a knock out? Sex Transm Infect 2010;86(6):415-421.
125. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefxime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15(47):pii=19721.
126. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefxime and azithromycin in England, 2010. Euro Surveill 2011;16(14):pii=19833.
127. Tapsall J W. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacifc Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009;85(4):256-258.
128. Fayemiwo S, Müller E, Gumede L, Lewis D. Plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in South Africa: Prevalence, detection and typing using a novel molecular assay. Sex Transm Dis 2011;38:329-333.
129. Cohen MS, Hofman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997;349(9069):1868-1873.
130. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2010. Geneva: UNAIDS, 2010:1-100. http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf (accessed 22 June 2011).
131. Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10(9):597-602.
132. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9(4):228-236.
133. Elliott E, Brink AJ, van Greune J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006;42(11):e95-98.
134. Bell JM, Turnidge JD, Jones RN. Prevalence of extended-spectrum beta-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001. Antimicrob Agents Chemother 2003;47(12):3989-3993.
135. Bell JM, Turnidge JD. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacifc and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob Agents Chemother 2002;46(3):879-881.
136. Brink AJ, Moolman J, Cruz da Silva M, and the National Antibiotic Surveillance Forum. Antimicrobial susceptibility profle of selected bacteraemic pathogens from private institutions in South Africa. S Afr Med J 2007;97:630-636.